Top

Archives of Gynecology and Obstetrics

Published in:

01-07-2016 | Gynecologic Endocrinology and Reproductive Medicine

Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis

Authors: Qiaomei Zheng, Hongluan Mao, Ying Xu, Jing Zhao, Xuan Wei, Peishu Liu

Published in: Archives of Gynecology and Obstetrics | Issue 1/2016

Abstract

Purpose

To investigate whether postoperative GnRH agonist (GnRH-a) treatment can prevent endometriosis recurrence.

Methods

This meta-analysis searched PubMed, Embase and Cochrane Library for relevant studies published online before June 2015. Seven randomized controlled trials including 328 patients with postoperative GnRH-a treatment and 394 patients in control group were included in the meta-analysis. In the meta-analysis, the recurrence rate of GnRH-a group compared with control group was evaluated with odds ratio (OR) and its 95 % confidence interval (CI). Heterogeneity, small study effect and publication bias were, respectively, assessed using Higgins I ², sensitivity analysis and funnel plot.

Results

Postoperative GnRH-a treatment for endometriosis (pooled OR = 0.71; 95 % CI 0.52–0.96) was superior to expectant or placebo treatment in prevention of the recurrence. The recurrence rate decreased significantly in patients who received 6 months GnRH-a treatment (pooled OR = 0.59, 95 % CI 0.38–0.90), whereas no significant difference of recurrence rate existed between patients with 3 months post-surgical GnRH-a therapy and the control group (pooled OR = 0.87, 95 % CI 0.56–1.34). No significant heterogeneity and small study effect were found in the meta-analysis. However, publication bias did existed in the present meta-analysis.

Conclusions

Longer-term (6 months) postoperative administration of GnRH-a can decrease the recurrence risk of endometriosis, whereas 3 months duration of GnRH-a therapy makes no significant difference in preventing the recurrence of endometriosis. Therefore, instead of a 3 month therapy, the duration of the postoperative administration should be longer enough (6 months) to prevent the recurrence of endometriosis.

Available only for authorised users

Eskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24(2):235–258CrossRefPubMed

Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29(3):400–412. doi:10.1093/humrep/det457 CrossRefPubMed

Fedele L, Bianchi S, Zanconato G, Berlanda N, Raffaelli R, Fontana E (2006) Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery. Fertil Steril 85(3):694–699. doi:10.1016/j.fertnstert.2005.08.028 CrossRefPubMed

Wheeler JM, Malinak LR (1983) Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 146(3):247–253CrossRefPubMed

Fedele L, Bianchi S, Di Nola G, Candiani M, Busacca M, Vignali M (1994) The recurrence of endometriosis. Ann N Y Acad Sci 734:358–364CrossRefPubMed

Weir E, Mustard C, Cohen M, Kung R (2005) Endometriosis: what is the risk of hospital admission, readmission, and major surgical intervention? J Minim Invasive Gynecol 12(6):486–493. doi:10.1016/j.jmig.2005.09.001 CrossRefPubMed

Cheong Y, Tay P, Luk F, Gan HC, Li TC, Cooke I (2008) Laparoscopic surgery for endometriosis: How often do we need to re-operate? J Obstet Gynaecol 28(1):82–85. doi:10.1080/01443610701811761 CrossRefPubMed

Kennedy S (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20(10):2698–2704. doi:10.1093/humrep/dei135 CrossRefPubMed

Jee BC, Lee JY, Suh CS, Kim SH, Choi YM, Moon SY (2009) Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after conservative laparoscopic surgery. Fertil Steril 91(1):40–45CrossRefPubMed

10.

Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P (1999) A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 106(7):672–677CrossRefPubMed

11.

Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL (1997) Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 5:860–864CrossRef

12.

Parazzini F, Fedele L, Busacca M, Falsetti L, Pellegrini S, Venturini PL, Stella M (1994) Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 171(5):1205–1207CrossRefPubMed

13.

Busacca M, Somigliana E, Bianchi S, De Marinis S, Calia C, Candiani M, Vignali M (2001) Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum Reprod 16(11):2399–2402PubMed

14.

Loverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L (2008) A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 136(2):194–198CrossRefPubMed

15.

Alborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi M (2011) A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet 284(1):105–110CrossRefPubMed

16.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12CrossRefPubMed

17.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj 327(7414):557–560. doi:10.1136/bmj.327.7414.557 PubMed

18.

Sesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E (2009) Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol Reprod Biol 147(1):72–77CrossRefPubMed

19.

Acién P, Quereda F, Campos A, Gomez-Torres MJ, Velasco I, Gutierrez M (2002) Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 4:705–711CrossRef

20.

Liu X, Yuan L, Shen F, Zhu Z, Jiang H, Guo SW (2007) Patterns of and risk factors for recurrence in women with ovarian endometriomas. Obstet Gynecol 109(6):1411–1420. doi:10.1097/01.AOG.0000265215.87717.8b CrossRefPubMed

21.

Regidor PA, Regidor M, Kato K, Bier UW, Buhler K, Schindler AE (1997) Long-term follow-up on the treatment of endometriosis with the GnRH- agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur(registered trademark)), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 73(2):153–160CrossRefPubMed

22.

Sesti F, Pietropolli A, Capozzolo T, Broccoli P, Pierangeli S, Bollea MR, Piccione E (2007) Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertil Steril 88(6):1541–1547CrossRefPubMed

23.

Mettler L, Ruprai R, Alkatout I (2014) Impact of medical and surgical treatment of endometriosis on the cure of endometriosis and pain. Biomed Res Int 2014:264653. doi:10.1155/2014/264653 CrossRefPubMedPubMedCentral

24.

Yap C, Furness S, Farquhar C (2004) Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev (3):CD003678. doi:10.1002/14651858.CD003678.pub2

25.

Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG (2003) Endometriosis: preoperative and postoperative medical treatment. Obstet Gynecol Clin North Am 30(1):163–180CrossRefPubMed

26.

Ferrero S, Abbamonte LH, Parisi M, Ragni N, Remorgida V (2007) Dyspareunia and quality of sex life after laparoscopic excision of endometriosis and postoperative administration of triptorelin. Fertil Steril 87(1):227–229. doi:10.1016/j.fertnstert.2006.06.018 CrossRefPubMed

27.

Hornstein MD, Yuzpe AA, Burry KA, Heinrichs LR, Buttram VL Jr, Orwoll ES (1995) Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 63(5):955–962PubMed

28.

Olive DL (2004) Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 3(2):83–89CrossRefPubMed

29.

Sagsveen M, Farmer JE, Prentice A, Breeze A (2003) Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev (4):CD001297. doi:10.1002/14651858.cd001297

30.

Howell R, Edmonds DK, Dowsett M, Crook D, Lees B, Stevenson JC (1995) Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 64(3):474–481CrossRefPubMed

31.

Kikuchi I, Takeuchi H, Kitade M, Shimanuki H, Kumakiri J, Kinoshita K (2006) Recurrence rate of endometriomas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand 85(9):1120–1124. doi:10.1080/00016340600627154 CrossRefPubMed

Title: Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis
Authors: Qiaomei Zheng
Hongluan Mao
Ying Xu
Jing Zhao
Xuan Wei
Peishu Liu
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 1/2016
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-016-4085-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Implementation of enhanced recovery after surgery (ERAS) in gynaecological oncology

Reply to letter to the editor by J.-M. Kim et al. on "Sexual function and quality of life in women with cervical cancer before radiotherapy: a pilot study" by Grion et al.

Ultrasonographic early diagnosis of osteogenesis imperfecta type I: implications for pre and post-natal therapy

Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy

Altered FoxO3 expression and apoptosis in granulosa cells of women with polycystic ovary syndrome

Robotic assisted vs laparoscopic and/or open myomectomy: systematic review and meta-analysis of the clinical evidence